Skip Navigation LinksHome > June 1, 2002 - Volume 30 - Issue 2 > Safety of Antiretroviral Prophylaxis of Perinatal Transmissi...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.QAI.0000018366.28828.86
Rapid Communications: PDF Only

Safety of Antiretroviral Prophylaxis of Perinatal Transmission for HIV-Infected Pregnant Women and Their Infants.

Mofenson, Lynne M.; Munderi, Paula

Collapse Box


: Worldwide, more than 1600 infants become infected with HIV each day. Almost all infections are a result of mother-to-child transmission of HIV, with most of these infections occurring in resource-poor countries. In developed countries, antiretroviral prophylaxis has dramatically reduced perinatal transmission to <2%. The potential now exists to extend this success to resource-poor countries using effective but shorter and less expensive antiretroviral regimens.

With the potential widespread use of antiretroviral therapy for perinatal HIV prevention in resource-limited settings, there will be exposure of increasing numbers of infants to in utero and postpartum antiretroviral drugs for which long-term toxicity data is unknown. This article focuses on a review of what is known about safety of antiretroviral regimens used to interrupt mother-to-child transmission for women and their children.

(C) 2002 Lippincott Williams & Wilkins, Inc.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.